ライフサイエンスコーパス: brand name

1 data were collected on specific chemicals or brand names.

2 porting on medications with both generic and brand names, 186 (67%; 95% CI, 61%-73%) referred to the

3 ts of 8.0% (difference of proportions versus brand-name, 7.5% [95% confidence interval, -0.9% to 15.9

4 ecutive years following adequate trials of 2 brand-name AEDs.

5 viation (total of 79 errors, 11.4%, for both brand name and generic name orders), incorrect dosage ca

6 ured by the occurrence rate of international brand names and trading volumes, is characterized by int

7 isource drug (that is, a drug available in a brand-name and > or =1 generic formulation) or a generic

8 No measures changed in the brand-name and generic coverage groups.

9 me countries, prices may be reduced for both brand-name and generic drugs, but the prevalence of unau

10 y are often concerned that switching between brand-name and generic formulations of antiepilepsy drug

11 3) What is the evidence that brand-name and generic medications have similar clinical

12 Monthly prescriptions of brand-name and generic-equivalent beta-blockers, statins

13 tance, preserving the department's academic "brand name," and ensuring consistent standards and opera

14 attributable to the reduction in the use of brand-name antidepressants.

15 ught consumer packaged goods (CPGs), whether brands (name brands compared with private labels) matter

16 or one of two porous glasses sold under the brand names CoralPor and Electro-porous KT.

17 and frequently refer to medications by their brand names despite newspaper editors' contention that t

18 Once the patent of a brand-name drug expires, generic drugs are commercialize

19 iotensin-receptor blockers (ARBs) who filled brand-name drug prescriptions and percentage of patients

20 at in all other countries, largely driven by brand-name drug prices that have been increasing in rece

21 Brand-name drug use in Medicare was 2 to 3 times that in

22 ulation would have been $1.4 billion less if brand-name drug use matched that of the VA.

23 the 95th-percentile HRR in the VA had lower brand-name drug use than the 5th-percentile HRR in Medic

24 atus-adjusted hospital referral region (HRR) brand-name drug use was compared, and changes in spendin

25 scribe the factors underlying differences in brand-name drug use.

26 ed a generic drug, and 6380 (7%) initiated a brand-name drug.

27 Of the 19 brand-name drugs analyzed, the retail prices of 7 drugs

28 ditional review pathways for newly available brand-name drugs and biosimilar medicines to treat serio

29 e with generic coverage reduced their use of brand-name drugs and did not switch from brand-name to g

30 creased to eventually include 120 additional brand-name drugs and their generic alternatives when ava

31 Clinicians should know that few brand-name drugs are widely covered and check coverage b

32 hanges in spending were calculated if use of brand-name drugs in 1 system mirrored the other.

33 Prices of surveyed brand-name drugs increased rapidly between 2009 and 2015

34 s concern among patients and physicians that brand-name drugs may be clinically superior to generic d

35 ases treated, or unusual price increases, 19 brand-name drugs surveyed in all 4 years were selected f

36 iciaries with diabetes use 2 to 3 times more brand-name drugs than a comparable group within the VA,

37 as evidence does not support the notion that brand-name drugs used in cardiovascular disease are supe

38 Overall, 73% of generic drugs and 6% of brand-name drugs were widely covered.

39 t's insurance coverage, refuses to prescribe brand-name drugs when generic alternatives are available

40 of generic drugs, which are bioequivalent to brand-name drugs, can help contain prescription drug spe

41 e initial survey requested information on 72 brand-name drugs.

42 The annual ratio of generic to brand-name fenofibrate use in the United States ranged f

43 oequivalence established between generic and brand-name formulations of an immunosuppressive drug in

44 Different water brands (different brand names) from the same geographical origin did not s

45 T20 (generic name: Enfuvirtide, brand name: Fuzeon) is the only FDA-approved HIV fusion

46 nts in the generic group versus those in the brand-name group (HR, 0.92 [95% CI, 0.86 to 0.99]).

47 n the generic group and 71% for those in the brand-name group (P<0.001).

48 ) referred to the study medications by their brand names in at least half of the medication reference

49 The 4 generic and brand-name levothyroxine preparations studied are differ

50 ce was defined as the screen appearance of a brand name, logo, or identifiable trademark on products

51 verse events was affected for generic versus brand-name losartan users only (difference of proportion

52 osts and generated the highest percentage of brand name medication claims compared with all other pro

53 Low-value services, such as prescribing brand-name medications that have existing generic equiva

54 out generic medications: 1) How commonly are brand-name medications used when a generic version is av

55 ility of free samples and the prescribing of brand-name medications, and the mean cost of acne medica

56 ons, if possible, rather than more expensive brand-name medications.

57 Relying on brand names of therapy can be misleading.

58 c had been substituted for all corresponding brand-name outpatient drugs in 2000, the median annual s

59 c latanoprost, patients who continued taking brand name PGAs were 28% less likely to have improved ad

60 ompared between persons who continued to use brand-name PGAs once generic latanoprost became availabl

61 e generic enoxaparin product relative to the brand name product.

62 Lead was present even in some brand name products from major pharmaceutical companies

63 , drug safety can be adequately ensured, and brand-name products are usually less expensive than in t

64 Adjusted HRR-level brand-name statin use ranged (from the 5th to 95th perce

65 Brand-name statins were used by 18.2% of statin users, a

66 Compared with those initiating brand-name statins, patients initiating generic statins

67 of brand-name drugs and did not switch from brand-name to generic drugs.

68 8), indicating no evidence of superiority of brand-name to generic drugs.

69 h statins decreased, further substitution of brand-name to generic statins may yield more savings.

70 gs are commercialized, and substitution from brand-name to generics may occur.

71 trodes, nanoporous glass frits (often of the brand named Vycor) contain the electrolyte solution that